Keyword: drug plan management

503 results found
Harnessing analytics, data to support employee mental health

Mental health is the third largest health spend in terms of benefits plan management, according to Derek Weir, manager of health benefit solutions at Medavie Blue Cross. “Fifty-three per cent of Canadians consider anxiety and depression ‘epidemic’ in Canada and 85 per cent say mental-health services are among the most underfunded in health care,” he said […]

What to expect for health benefits in 2020

Looking ahead to 2020, the big story for health benefits is often avoided because it isn’t easy to address. It’s the elephant in the room. Over the past year, there’s been no shortage of momentum in new and emerging product offerings in the health benefits space — everything from digital cognitive behavioural therapy to virtual […]

  • December 24, 2019 November 12, 2020
  • 06:30
iA Financial launches medication adherence pilot project

iA Financial Group is launching a pilot project to help benefits plan members with medication adherence. The Quebec City-based insurer will offer access to mobile app MedHelper to a few thousand plan members who are taking three or more medications on a daily basis. The plan members can import the list of drugs they take into the […]

Express Scripts Canada rolls out medication non-adherence detection program

Express Scripts Canada is launching a medication non-adherence, early-detection program in 2020 to identify plan members who are most likely to cease taking their prescription medications. The program will use proprietary predictive modelling to analyze prescription drug claims and determine who is at risk for potential non-adherence in the future, according to a press release. “Encouraging adherence […]

  • By: Staff
  • November 27, 2019 November 12, 2020
  • 09:45
Draft PMPRB guidelines include changes to reference countries, drug price factors

The Patented Medicine Prices Review Board has published draft guidelines, including new factors for setting patented drug prices and an updated list of reference countries for Canada to compare its prices. The guidelines were updated to address the federal government’s final amendments to the PMPRB rules, which were released in August. The board is seeking comment from stakeholders until Jan. 20, […]

  • By: Staff
  • November 25, 2019 November 12, 2020
  • 09:15
HumanisRx launches medication optimization program

Medication-related issues are negatively affecting employees’ health, causing them to take extended leaves from their jobs and leading to high benefits and disability costs for employers, according to a new white paper by HumanisRx. These issues include incompatible or duplicate drugs, higher than recommended doses, suboptimal therapy and failure to take medications as prescribed. “Our research finds […]

  • By: Staff
  • November 14, 2019 November 12, 2020
  • 15:00
Proposed changes to Ontario drug rules target generics pricing, biosimilar listing process

Ontario has proposed amendments to provincial drug regulations that aim to change the pricing model for generic drugs and simplify the process for the province’s drug formulary to list biosimilars. Ontario’s Ministry of Health and Long-Term Care said the changes are aimed at reducing the “administrative burden” for drug manufacturers and pharmacies. With regards to […]

  • By: Staff
  • November 14, 2019 November 12, 2020
  • 09:00
Conference coverage: 2019 Calgary Drug Trends Summit

On Oct. 24, the 2019 Calgary Drug Trends Summit featured presentations to educate plan sponsors and advisors about specific disease states and their challenges, new drug treatment categories and key drug trends facing benefits plans. Here’s what you missed! New drug therapies for common conditions could impact private plan sustainability While medical advancements and drug […]

New drug therapies for common conditions could impact private plan sustainability

While medical advancements and drug therapy innovations have been life-changing for patients and plan members, they also come with increasing costs, said Victoria Shaw, drug benefits manager at Alberta Blue Cross, speaking at Benefits Canada’s 2019 Calgary Drug Trends Summit on Oct. 24. Between 2011 to 2017, the number of high-cost drugs doubled. From 2016 to 2017, in […]

Switch from biologic to biosimilar drug requires monitoring, patient-informed discussion

When it comes to switching from a biologic to a biosimilar drug, patient choice and engagement is extremely important, according to Durhane Wong-Rieger, president and chief executive officer of the Canadian Organization for Rare Disorders.  “While a patient’s on a drug, they need to be continuously monitoring,” she said during a session at Benefits Canada’s 2019 Calgary Drug […]